ArticleBMC pulmonary medicine2026
Di̇agnosti̇c yi̇eld of EBUS i̇n medi̇asti̇nal stagi̇ng of extrapulmonary mali̇gnanci̇es; si̇ngle center cli̇ni̇cal experi̇ence.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate mediastinal staging is essential for treatment planning and prognostic assessment in patients with extrapulmonary malignancies. Endobronchial ultrasonography (EBUS) has emerged as a minimally invasive modality for mediastinal evaluation; however, evidence regarding its diagnostic performance in extrapulmonary malignancies remains limited.
methodsPatients with known extrapulmonary malignancies who underwent EBUS for mediastinal staging were retrospectively analyzed. Demographic characteristics, radiological findings, sampled lymph node stations, and pathological results were evaluated. Factors potentially associated with malignant mediastinal involvement were assessed.
resultsEBUS enabled successful sampling of mediastinal and hilar lymph nodes across multiple stations. Malignant involvement was identified in a subset of patients, while benign etiologies—including reactive and granulomatous lymphadenopathy—accounted for the majority of cases. Increased lymph node diameter was associated with malignancy, whereas primary tumor type and the number of sampled lymph nodes were not independent predictors of malignant pathology.
conclusionsEBUS appears to be a safe and reliable tool for mediastinal staging in patients with extrapulmonary malignancies. Its minimally invasive nature and diagnostic performance support its use as a first-line modality, potentially reducing the need for confirmatory mediastinoscopy in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.